236 related articles for article (PubMed ID: 23085756)
1. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.
Martino JJ; Wall BA; Mastrantoni E; Wilimczyk BJ; La Cava SN; Degenhardt K; White E; Chen S
Oncogene; 2013 Sep; 32(37):4366-76. PubMed ID: 23085756
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.
Teh JL; Shah R; La Cava S; Dolfi SC; Mehta MS; Kongara S; Price S; Ganesan S; Reuhl KR; Hirshfield KM; Karantza V; Chen S
Breast Cancer Res Treat; 2015 May; 151(1):57-73. PubMed ID: 25859923
[TBL] [Abstract][Full Text] [Related]
3. AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1).
Shin SS; Wall BA; Goydos JS; Chen S
Pigment Cell Melanoma Res; 2010 Feb; 23(1):103-11. PubMed ID: 19843246
[TBL] [Abstract][Full Text] [Related]
4. Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.
Marín YE; Namkoong J; Cohen-Solal K; Shin SS; Martino JJ; Oka M; Chen S
Cell Signal; 2006 Aug; 18(8):1279-86. PubMed ID: 16305822
[TBL] [Abstract][Full Text] [Related]
5. Functional effects of GRM1 suppression in human melanoma cells.
Wangari-Talbot J; Wall BA; Goydos JS; Chen S
Mol Cancer Res; 2012 Nov; 10(11):1440-50. PubMed ID: 22798429
[TBL] [Abstract][Full Text] [Related]
6. Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1
Shah R; Singh SJ; Eddy K; Filipp FV; Chen S
Cancer Res; 2019 Apr; 79(8):1799-1809. PubMed ID: 30987979
[TBL] [Abstract][Full Text] [Related]
7. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.
Le MN; Chan JL; Rosenberg SA; Nabatian AS; Merrigan KT; Cohen-Solal KA; Goydos JS
J Invest Dermatol; 2010 Sep; 130(9):2240-9. PubMed ID: 20505744
[TBL] [Abstract][Full Text] [Related]
8. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.
Namkoong J; Shin SS; Lee HJ; Marín YE; Wall BA; Goydos JS; Chen S
Cancer Res; 2007 Mar; 67(5):2298-305. PubMed ID: 17332361
[TBL] [Abstract][Full Text] [Related]
10. Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.
Teh JL; Shah R; Shin SS; Wen Y; Mehnert JM; Goydos J; Chen S
Pigment Cell Melanoma Res; 2014 Jul; 27(4):621-9. PubMed ID: 24628914
[TBL] [Abstract][Full Text] [Related]
11. Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.
Wall BA; Wangari-Talbot J; Shin SS; Schiff D; Sierra J; Yu LJ; Khan A; Haffty B; Goydos JS; Chen S
Pigment Cell Melanoma Res; 2014 Mar; 27(2):263-74. PubMed ID: 24330389
[TBL] [Abstract][Full Text] [Related]
12. Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1.
Speyer CL; Nassar MA; Hachem AH; Bukhsh MA; Jafry WS; Khansa RM; Gorski DH
Breast Cancer Res Treat; 2016 Jun; 157(2):217-228. PubMed ID: 27146584
[TBL] [Abstract][Full Text] [Related]
13. Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.
Wen Y; Li J; Koo J; Shin SS; Lin Y; Jeong BS; Mehnert JM; Chen S; Cohen-Sola KA; Goydos JS
Cancer Res; 2014 May; 74(9):2499-509. PubMed ID: 24491800
[TBL] [Abstract][Full Text] [Related]
14. Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.
Speyer CL; Smith JS; Banda M; DeVries JA; Mekani T; Gorski DH
Breast Cancer Res Treat; 2012 Apr; 132(2):565-73. PubMed ID: 21681448
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation.
Shin SS; Namkoong J; Wall BA; Gleason R; Lee HJ; Chen S
Pigment Cell Melanoma Res; 2008 Jun; 21(3):368-78. PubMed ID: 18435704
[TBL] [Abstract][Full Text] [Related]
16. Glutamatergic signaling in cellular transformation.
Teh JL; Chen S
Pigment Cell Melanoma Res; 2012 May; 25(3):331-42. PubMed ID: 22273393
[TBL] [Abstract][Full Text] [Related]
17. A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.
Yip D; Le MN; Chan JL; Lee JH; Mehnert JA; Yudd A; Kempf J; Shih WJ; Chen S; Goydos JS
Clin Cancer Res; 2009 Jun; 15(11):3896-902. PubMed ID: 19458050
[TBL] [Abstract][Full Text] [Related]
18. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.
Banda M; Speyer CL; Semma SN; Osuala KO; Kounalakis N; Torres Torres KE; Barnard NJ; Kim HJ; Sloane BF; Miller FR; Goydos JS; Gorski DH
PLoS One; 2014; 9(1):e81126. PubMed ID: 24404125
[TBL] [Abstract][Full Text] [Related]
19. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
[TBL] [Abstract][Full Text] [Related]
20. Genetic inactivation of mGlu5 receptor improves motor coordination in the Grm1
Bossi S; Musante I; Bonfiglio T; Bonifacino T; Emionite L; Cerminara M; Cervetto C; Marcoli M; Bonanno G; Ravazzolo R; Pittaluga A; Puliti A
Neurobiol Dis; 2018 Jan; 109(Pt A):44-53. PubMed ID: 28982591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
